ELOHIMED is a French Start-up specializing in the research and development of new drugs and bioactive compositions against cancer.

Our project aims to develop a new drug indicated for the treatment of cancer and its various complications. To this end, we are looking for a consortium via the HORIZON-HLTH-2026-01-DISEASE-09 call to optimize in vivo preclinical development and clinical phases leading to patient access to a reliable drug.

Our composition targets specifically in the tumor microenvironment, cells that overexpress Reptin and/or Pontin, and also a large number of proteins involved in cell survival and resistance to cytotoxic chemotherapy. Indeed, the effectiveness of aggressive chemotherapy and so-called "targeted" therapies remains limited by significant side effects, resistance phenomena relayed by the tumor microenvironment, and by tumor cells in a state of quiescence in the bone marrow. This pharmaceutical composition inhibits the production of soluble factors in the tumor microenvironment, which are not only involved in the recruitment of macrophages and the amplification of the inflammatory process, but also contribute to angiogenesis, epithelial-mesenchymal transition and metastasis.

This innovative pharmaceutical combination is part of a global and synergistic therapeutic strategy aimed at inhibiting cell growth, causing the death of tumor cells, but above all to break the link between the tumor microenvironment and the bone marrow, source of many cells that colonize the primary tumor and also form the premetastatic niche.

Preclinical trials were conducted on the Hep3B cell line of Hepatocellular Carcinoma, the DU-145 cell line of prostate cancer and the MCF-7 cell line of breast cancer with very encouraging results.